A 28-Day Parallel Group Study of TD-4208 in COPD
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 5/5/2014 |
| Start Date: | March 2014 |
| End Date: | October 2014 |
| Contact: | Andrew Nicholls, MD |
| Email: | Anicholls@theravance.com |
| Phone: | 650-808-6400 |
A Phase IIB, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
This study will evaluate the safety and efficacy of four doses of TD-4208 and a placebo
product when administered once daily for 28 days using a jet nebulizer to patients with
moderate to severe chronic obstructive pulmonary disease.
product when administered once daily for 28 days using a jet nebulizer to patients with
moderate to severe chronic obstructive pulmonary disease.
Inclusion Criteria:
- Subject is a male or female subject 40 years of age or older
- Subject must have a negative pregnancy test, and must be prepared to use effective
contraception if of child-bearing potential
- Subject is capable of performing reproducible spirometry maneuvers
- Subject has post-bronchodilator FEV1/FVC ratio <0.7
- Subject has moderate-to-severe stable COPD (Stage 2 or 3 according to the GOLD
Guidelines)
- Subject has a post-bronchodilator FEV1 greater than or equal to 30% and less than 80%
of predicted normal
- Subject has a current or past smoking history of at least 10 pack-years.
Exclusion Criteria:
- Subject has a significant respiratory disease or disorder other than COPD that would
affect the interpretation of data from this study
- Subject has a history of reactions or hypersensitivity to inhaled or nebulized
anticholinergic or beta-agonist agents
- Subject suffers from any medical condition that would preclude the use of inhaled
anticholinergic agents
- Subject has been hospitalized for COPD or pneumonia within 12 weeks
- Subject requires long-term oxygen therapy (>15 hours a day)
We found this trial at
1
site
